|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCGN |
Gene summary for SCGN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCGN | Gene ID | 10590 |
| Gene name | secretagogin, EF-hand calcium binding protein | |
| Gene Alias | CALBL | |
| Cytomap | 6p22.2 | |
| Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | O76038 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10590 | SCGN | S43 | Human | Liver | Cirrhotic | 4.22e-11 | -4.86e-01 | -0.0187 |
| 10590 | SCGN | HCC1_Meng | Human | Liver | HCC | 9.16e-55 | -6.07e-02 | 0.0246 |
| 10590 | SCGN | HCC2_Meng | Human | Liver | HCC | 4.05e-12 | -5.15e-01 | 0.0107 |
| 10590 | SCGN | cirrhotic1 | Human | Liver | Cirrhotic | 1.32e-12 | 5.37e-02 | 0.0202 |
| 10590 | SCGN | cirrhotic2 | Human | Liver | Cirrhotic | 9.25e-14 | 5.71e-02 | 0.0201 |
| 10590 | SCGN | cirrhotic3 | Human | Liver | Cirrhotic | 1.23e-04 | -2.84e-01 | 0.0215 |
| 10590 | SCGN | HCC5 | Human | Liver | HCC | 1.53e-04 | -5.20e-01 | 0.4932 |
| 10590 | SCGN | Pt13.a | Human | Liver | HCC | 1.08e-13 | -5.13e-01 | 0.021 |
| 10590 | SCGN | Pt13.b | Human | Liver | HCC | 2.19e-09 | -5.20e-01 | 0.0251 |
| 10590 | SCGN | Pt13.c | Human | Liver | HCC | 1.20e-05 | -5.20e-01 | 0.0076 |
| 10590 | SCGN | Pt14.d | Human | Liver | HCC | 3.01e-11 | -5.12e-01 | 0.0143 |
| 10590 | SCGN | S014 | Human | Liver | HCC | 3.55e-03 | -4.76e-01 | 0.2254 |
| 10590 | SCGN | S027 | Human | Liver | HCC | 2.17e-04 | 1.26e+00 | 0.2446 |
| 10590 | SCGN | S028 | Human | Liver | HCC | 2.85e-15 | 1.51e+00 | 0.2503 |
| 10590 | SCGN | S029 | Human | Liver | HCC | 2.31e-12 | 1.50e+00 | 0.2581 |
| 10590 | SCGN | HTA12-15-2 | Human | Pancreas | PDAC | 1.08e-16 | 1.01e+00 | 0.2315 |
| 10590 | SCGN | HTA12-23-1 | Human | Pancreas | PDAC | 4.86e-11 | 9.98e-01 | 0.3405 |
| 10590 | SCGN | HTA12-25-1 | Human | Pancreas | PDAC | 1.42e-09 | 8.76e-01 | 0.313 |
| 10590 | SCGN | HTA12-26-1 | Human | Pancreas | PDAC | 9.47e-26 | 1.12e+00 | 0.3728 |
| 10590 | SCGN | HTA12-29-1 | Human | Pancreas | PDAC | 1.57e-39 | 8.62e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCGN | SNV | Missense_Mutation | novel | c.719N>G | p.Val240Gly | p.V240G | O76038 | protein_coding | tolerated(0.37) | benign(0.001) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCGN | SNV | Missense_Mutation | novel | c.458A>G | p.Tyr153Cys | p.Y153C | O76038 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SCGN | SNV | Missense_Mutation | rs200726171 | c.295N>T | p.Arg99Cys | p.R99C | O76038 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| SCGN | SNV | Missense_Mutation | c.544G>A | p.Glu182Lys | p.E182K | O76038 | protein_coding | deleterious(0.01) | benign(0.071) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SCGN | SNV | Missense_Mutation | c.112G>A | p.Asp38Asn | p.D38N | O76038 | protein_coding | tolerated(0.05) | benign(0.019) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SCGN | SNV | Missense_Mutation | c.344G>A | p.Arg115His | p.R115H | O76038 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SCGN | SNV | Missense_Mutation | c.741G>T | p.Glu247Asp | p.E247D | O76038 | protein_coding | tolerated(0.15) | benign(0.005) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| SCGN | SNV | Missense_Mutation | rs567158105 | c.298N>T | p.Arg100Trp | p.R100W | O76038 | protein_coding | tolerated(0.18) | benign(0.022) | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD |
| SCGN | SNV | Missense_Mutation | novel | c.531N>G | p.Ile177Met | p.I177M | O76038 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SCGN | SNV | Missense_Mutation | novel | c.172N>C | p.Asn58His | p.N58H | O76038 | protein_coding | tolerated(0.12) | benign(0.109) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |